CD52 (CAMPATH-1) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-CD52 (CAMPATH-1) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD52 (CAMPATH-1) |
| Clone | polyclonal |
| Host Species | Rat |
| Reactive Species | human |
| Isotype | n/a |
| Format | unconjugated |
| Size | 0.2 mL |
| Concentration | 1 mg/ml |
| Applications | Immunohistochemistry (IHC), ELISA (EIA), Western Blot (WB), Flow Cytometry (FC/FACS) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | This antibody reacts with the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small peptide that is heavily glycosylated, and attached to the cell surface membrane via a GPI link. The apparent molecular mass of the antigen on SDS-PAGE is 25-29kD. CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.Humanised versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies. |
| Immunogen | n/a |
| Other Names | n/a |
| Gene, Accession # | [CD52] |
| Catalog # | MBS397395 |
| Price | $1105 |
| Order / More Info | CD52 (CAMPATH-1) Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Hale, G. et al. (1998). Improving the Outcome of Bone Marow Transplantation by using CD52 Monoclonal Antibodies to prevent graft-versus-host disease and graft rejection. Blood 92: 4581-4590. 2. Salisbury, J.R. et al. (1994). Immunohistochemical analysis of CDw52 antigen expression in non-hodgkins lymphomas. J. Clin. Path. 47: 313-317. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies